Irma Rahayu Latarissa

Irma Rahayu Latarissa

Auto-generated profile, based on publicly available information

Irma Rahayu Latarissa

Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Experimental Pharmacology
Verified
Journal Article
Open access
PDF file
ISIda Ayu Manik Partha Sutema
Ida Ayu Manik Partha Sutema
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
IWI Gusti Ayu Rai Widowati
I Gusti Ayu Rai Widowati
CSCynthia Retna Sartika
Cynthia Retna Sartika
NCNi Wayan Eka Ciptasari
Ni Wayan Eka Ciptasari
KLKeri Lestari
Keri Lestari
Acne vulgaris is a prevalent dermatological condition characterized by comedones, papules, and pustules, with significant physical and psychological implications. Conventional treatments for this condition, including antibiotics and retinoids, face challenges, such as side effects and antibiotic resistance, necessitating alternative treatments. Recent studies show the potential of probiotics to modulate skin microbiome and alleviate acne symptoms. Therefore, this study aimed to consolidate evidence from randomized controlled trials (RCTs) and clinical investigations, evaluating the efficacy of probiotics in acne management. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane databases using several keywords, such as “probiotic”, “microbiome”, and “acne vulgaris”. Inclusion criteria are RCTs and clinical studies from 2009 to 2024 examining probiotics for acne treatment. Studies were selected, screened, and analyzed based on population, intervention, design, and results. Descriptive statistics were used to summarize study characteristics. Fifteen studies including 811 participants met the inclusion criteria. The studies tested various oral and topical probiotics, including Lactobacillus, Bifidobacterium, Bacillus, and Enterococcus strains, over treatment periods ranging from 4 to 12 weeks. The results showed that probiotics, reduced acne lesions, improved skin barrier function, and decreased inflammatory markers. Both oral and topical probiotics showed potential in balancing skin microbiome and reducing acne severity. Some studies reported outcomes comparable to conventional acne treatments, such as antibiotics and benzoyl peroxide. However, there is variability in individual responses to different probiotic strains, and potential side effects, though rare, have been reported in some cases. Probiotics presented a natural, effective alternative to conventional acne treatment. However, future studies are needed to determine optimal treatment protocols.

1 October 2024 in Journal of Experimental Pharmacology
Verified
Journal Article
Open access
PDF file
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
Farida RendrayaniFarida Rendrayani
Farida Rendrayani
GIGhina Nadhifah Iftinan
Ghina Nadhifah Iftinan
CSCecep Suhandi
Cecep Suhandi
AMAnna Meiliana
Anna Meiliana
KLKeri Lestari
Keri Lestari
The COVID-19 pandemic is prompting extensive investigation into potential treatments, including the use of corticosteroids to manage inflammation and mitigate severe disease outcomes. Therefore, this systematic review aimed to evaluate the efficacy of oral/intravenous corticosteroids in the management of COVID-19. A comprehensive search was conducted across major scientific databases such as MEDLINE, Scopus, and Cochrane for relevant studies published from 2019– 2024. The inclusion criteria included studies investigating the use of oral/intravenous corticosteroids in COVID-19 patients > 18 years with a randomized placebo-controlled trial method. Non-placebo-controlled studies, studies using combined treatments with other drugs, as well as protocol articles, conference proceedings, review articles, and non-English studies were excluded. A narrative synthesis approach was adopted given the significant methodological diversity. The results showed that a total of 12 studies met the inclusion criteria covering the use of three drugs, including dexamethasone (three), hydrocortisone (two), and methylprednisolone (seven). The outcome parameters used for each study were different. Among the total 12 studies, five showed insignificant results for hydrocortisone (two) and methylprednisolone (three), while others reported significant results. This systematic review suggested that oral/intravenous corticosteroids might confer clinical benefits in the management of COVID-19, particularly in reducing mortality and severe disease outcomes. However, further investigation was needed to establish standardized protocols regarding dosage, duration, and safety considerations to optimize efficacy and minimize potential adverse effects.

1 January 2025 in Clinical Pharmacology: Advances and Applications
Verified
Journal Article
Open access
PDF file
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
MKMiski Aghnia Khairinisa
Miski Aghnia Khairinisa
GIGhina Nadhifah Iftinan
Ghina Nadhifah Iftinan
AMAnna Meiliana
Anna Meiliana
ISIda Paulina Sormin
Ida Paulina Sormin
KLKeri Lestari
Keri Lestari
Various repurposing drugs have been tested for their efficacy on coronavirus disease 2019 (COVID-19), including antimalarial drugs. During the pandemic, Chloroquine (CQ) and Hydroxychloroquine (HCQ) demonstrated good potential against COVID-19, but further studies showed both drugs had side effects that were more dangerous than the efficacy. This made World Health Organization (WHO) ban the usage for COVID-19 patients. In this context, there is a need to explore other antimalarial drugs as potential therapies for COVID-19. This study provides a descriptive synthesis of clinical trials evaluating antimalarial drugs for COVID-19 treatment conducted after the withdrawal of CQ and HCQ. The method was a literature study using the keywords “antimalarial”, “COVID-19”, “SARS-CoV-2”, “clinical trial”, and “randomized controlled trial” on the MEDLINE, Scopus, and Cochrane databases. Inclusion criteria were published clinical trials with randomized controlled trials (RCTs) on the efficacy and safety of single antimalarial drugs for COVID-19, published in English and excluding combination therapies. The results showed 3 antimalarial drugs, namely Quinine Sulfate (QS), Atovaquone (AQ), and Artemisinin-Piperaquine (AP), had gone through clinical trial to assess efficacy and safety against COVID-19 patients. Out of the 3 drugs, only AP showed significant results in the primary outcome, which was the time required to reach undetectable levels of SARS-CoV-2. Furthermore, the intervention group took 10.6 days, and the control group took 19.3 days (p=0.001). Based on this review, AP showed significant potential as a therapy in the fight against COVID-19.

1 January 2025 in Open Access Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
AMAnna Meiliana
Anna Meiliana
NDNurrani Mustika Dewi
Nurrani Mustika Dewi
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
MBMelisa Intan Barliana
Melisa Intan Barliana
SASofa Dewi Alfian
Sofa Dewi Alfian
AWAndi Wijaya
Andi Wijaya
Background: Sarcopenia is characterized by the progressive loss of skeletal muscle mass and poses a significant health challenge for older adults by increasing the risk of disability and decreasing quality of life. Yoga considers as a low-risk and beneficial exercise for older adults. This research aims to evaluate the potential of yoga practice as a preventive strategy against sarcopenia in Indonesian older adults. Methods: An observational cross-sectional research was conducted including 41 older adults aged 60– 87 years. The research focused on key biomarkers and functional assessments, including serum insulin-like growth factor 1 (IGF-1) levels, telomere length, gait speed, hand grip strength, and SARC-F questionnaire scores. Results: The results showed that participants aged 71– 80 years who practiced yoga for more than a year had significantly higher IGF-1 levels (p=0.04). While improvements in gait speed, hand grip strength, and SARC-F scores were observed, these changes were not statistically significant, and no significant differences were found in telomere length. Conclusion: Yoga in older adults was associated with higher IGF-1 levels and potential improvements in upper and lower extremity strength, though these findings were not statistically significant and did not influence telomere length. Yoga practice shows potential as an emerging adjuvant option but can not be applied as a single strategy for sarcopenia prevention in older adults.

1 August 2024 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
NPNorisca Aliza Putriana
Norisca Aliza Putriana
DDDika Pramita Destiani
Dika Pramita Destiani
APAdinda Naswa Putri
Adinda Naswa Putri
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
Purpose: This study aimed to examine the quality of life of patients receiving warfarin therapy at Dr. Hasan Sadikin Central General Hospital, and its relationship with demographic factors. Patients and Methods: The procedures started with the submission of a study permit, followed by validation of the Duke Anticoagulation Satisfaction Scale (DASS) questionnaire. In addition, the validated questionnaire was completed by the participants, and significant variables were analyzed using the chi-square method for multivariate analysis. Results: The results showed that the questionnaire was valid and could be used for further analyses. Among the 88 selected participants, 52 and 36 had scoring categories < 56.266 and 56.266 ≤ x ≤ 143.734, respectively, with no patients having a scoring category > 143.734. In addition, participants with low education and aged ≥ 52 years were 4.916 and 3.161 times more at risk of having quality of life score of 56.266 ≤ x ≤ 143.734, respectively. Based on the results, the average quality of life score of patients was 59.66. Participants with low educational levels and those aged ≥ 52 years were at a higher risk of having quality of life score of 56.266 ≤ x ≤ 143.734. Conclusion: In summary, a lower quality of life score was linked to increased comfort and satisfaction among patients receiving warfarin treatment. Additionally, these patients experienced fewer feelings of limitations and inconveniences related to their treatment plans.

1 January 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
SASyah Akbarul Adha
Syah Akbarul Adha
NANadiya Nurul Afifah
Nadiya Nurul Afifah
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
GIGhina Nadhifah Iftinan
Ghina Nadhifah Iftinan
AKArif Satria Wira Kusuma
Arif Satria Wira Kusuma
KLKeri Lestari
Keri Lestari
Diabetes mellitus (DM) is recognized and classified as a group of conditions marked by persistent high blood glucose levels. It is also an inflammatory condition that may influence concurrent disease states, including Coronavirus Disease 2019 (COVID-19). Currently, no effective drug has been found to treat COVID-19, especially in DM patients. Many herbal medicines, such as the well-known Andrographis paniculata, have been explored as drugs and complementary therapies due to their antidiabetic, antibacterial, antiviral, anti-inflammatory, and immunomodulatory effects. This study aimed to examine the potential of herbal medicines as complementary therapy in DM patients with COVID-19 complications, drawing from in-vitro and in-vivo investigations. This study analyzed articles published within the last 15 years using keywords including “herbal medicines”, “COVID-19”, “Diabetes Mellitus”, “antidiabetics”, “antiviral”, and “anti-inflammatory”. The results showed that several herbal medicines could serve as complementary therapy for DM patients with COVID-19 complications. These include Andrographis paniculata, Ageratum conyzoides, Artocarpus altilis, Centella asiatica, Momordica charantia, Persea gratissima, Phyllanthus urinaria, Physalis angulata, Tinospora cordifolia, and Zingiber zerumbet. Herbal medicines may serve as a complementary therapy for DM patients with COVID-19, but these claims need experimental validation in infection models and among affected patients.